

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims

Claims 1- 49 (Cancelled)

Claim 50. (Currently Amended) A process for modulating an immune response in a mammalian subject comprising administering to said subject an effective amount of a mammalian metabolite so as to modulate or change at least one component in the immune system of said subject, wherein the mammalian metabolite is a glycolipid, and wherein the immune response is part of the pathogenesis of a disease comprising an infection or an immune dysfunction.

Claim 51. (Original) The process of claim 50, wherein said immune system component comprises cellular, humoral or cytokine elements.

Claim 52. (Original): The process of claim 50, wherein said modulation or change is specific or non-specific.

--- Claim 53-54 (Cancelled).

Claim 55. (Previously Presented): The process of claim 50, wherein said glycolipid comprises a monosaccharide ceramide.

Claim 56. (Previously Presented) The process of claim 55, wherein said monosaccharide ceramide comprises a β -glucosylceramide or β -galactosylceramide.

Claim 57. (Original) The process of claim 50, wherein said administering step is carried out by means comprising intravenous means, intra-muscular means, subcutaneous means, intraperitoneal means or oral means.

Claim 58. (Cancelled) The process of claim 50, wherein said disease comprises cancer, an infection or immune dysfunction.

Claim 59. (Original) The process of claim 58, wherein said infection is viral or bacterial.

Claim 60. (Original) The process of claim 59, wherein said viral infection comprises HBV, HCV, or HIV.

Claim 61. (Withdrawn) The process of claim 58, wherein said immune dysfunction comprises diabetes type I, diabetes type II, rheumatoid arthritis, Crohn' s disease, arteriosclerosis and ulcerative colitis.

Claim 62. (Previously Presented) The process of claim 50, wherein said mammalian subject is a human.
